{"corpus_id":13512160,"paper_sha":"3337e258321c2555637f7529a0e7dd78eb1adb92","doi":"10.1136/jnnp.2005.074203","arxiv_id":null,"pmid":16157661,"pmcid":"PMC2077578","mag_id":2119186079,"dblp_id":null,"acl_id":null,"title":"Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register","year":2005,"publication_date":"2005-09-12","venue":"Journal of Neurology Neurosurgery & Psychiatry","journal":{"name":"Journal of Neurology, Neurosurgery & Psychiatry","pages":"193 - 198","volume":"77"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle"],"pubmed_pub_types":["Journal Article","Research Support, Non-U.S. Gov't"],"s2_fields_of_study":["Medicine"],"reference_count":39,"citation_count":767,"influential_citation_count":48,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Anticonvulsants","mj":false,"qs":[{"q":"administration & dosage","mj":false,"ui":"Q000008"},{"q":"toxicity","mj":true,"ui":"Q000633"}],"ui":"D000927"},{"d":"Dose-Response Relationship, Drug","mj":false,"ui":"D004305"},{"d":"Drug Therapy, Combination","mj":false,"ui":"D004359"},{"d":"Epilepsy","mj":false,"qs":[{"q":"drug therapy","mj":true,"ui":"Q000188"}],"ui":"D004827"},{"d":"Female","mj":false,"ui":"D005260"},{"d":"Follow-Up Studies","mj":false,"ui":"D005500"},{"d":"Gestational Age","mj":false,"ui":"D005865"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Infant, Newborn","mj":false,"ui":"D007231"},{"d":"Pregnancy","mj":false,"ui":"D011247"},{"d":"Pregnancy Complications","mj":false,"qs":[{"q":"drug therapy","mj":true,"ui":"Q000188"}],"ui":"D011248"},{"d":"Pregnancy Outcome","mj":false,"ui":"D011256"},{"d":"Prospective Studies","mj":false,"ui":"D011446"},{"d":"Registries","mj":true,"ui":"D012042"},{"d":"Risk","mj":false,"ui":"D012306"}],"chemicals":[{"n":"Anticonvulsants","ui":"D000927","reg":"0"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://jnnp.bmj.com/content/jnnp/77/2/193.full.pdf","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/3337e258321c2555637f7529a0e7dd78eb1adb92","s2_open_access_license":null,"s2_open_access_status":"BRONZE","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"OBJECTIVE: To assess the relative risk of major congenital malformation (MCM) from in utero exposure to antiepileptic drug (AEDs). METHODS: Prospective data collected by the UK Epilepsy and Pregnancy Register were analysed. The presence of MCMs recorded within the first three months of life was the main outcome measure. RESULTS: Full outcome data were collected on 3607 cases. The overall MCM rate for all AED exposed cases was 4.2% (95% confidence interval (CI), 3.6% to 5.0%). The MCM rate was higher for polytherapy (6.0%) (n = 770) than for monotherapy (3.7%) (n = 2598) (crude odds ratio (OR) = 1.63 (p = 0.010), adjusted OR = 1.83 (p = 0.002)). The MCM rate for women with epilepsy who had not taken AEDs during pregnancy (n = 239) was 3.5% (1.8% to 6.8%). The MCM rate was greater for pregnancies exposed only to valproate (6.2% (95% CI, 4.6% to 8.2%) than only to carbamazepine (2.2% (1.4% to 3.4%) (OR = 2.78 (p<0.001); adjusted OR = 2.97 (p<0.001)). There were fewer MCMs for pregnancies exposed only to lamotrigine than only to valproate. A positive dose response for MCMs was found for lamotrigine (p = 0.006). Polytherapy combinations containing valproate carried a higher risk of MCM than combinations not containing valproate (OR = 2.49 (1.31 to 4.70)). CONCLUSIONS: Only 4.2% of live births to women with epilepsy had an MCM. The MCM rate for polytherapy exposure was greater than for monotherapy exposure. Polytherapy regimens containing valproate had significantly more MCMs than those not containing valproate. For monotherapy exposures, carbamazepine was associated with the lowest risk of MCM.","claims":[{"public_id":"cl_46211c0f8f1b72c99abd0c69bfde5f24","status":"active","text":"Among live births to women with epilepsy exposed to antiepileptic drugs, the overall major congenital malformation rate was 4.2%.","confidence":0.99,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_46211c0f8f1b72c99abd0c69bfde5f24"},{"public_id":"cl_488c05f1888de037981fab35648c3060","status":"active","text":"Carbamazepine had the lowest major congenital malformation risk among monotherapy exposures, while lamotrigine showed a positive dose-response relationship with major congenital malformations.","confidence":0.94,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_488c05f1888de037981fab35648c3060"},{"public_id":"cl_747551a5e10238c4e2b6fd41ec233314","status":"active","text":"Major congenital malformation risk was higher with polytherapy than with monotherapy.","confidence":0.98,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_747551a5e10238c4e2b6fd41ec233314"},{"public_id":"cl_59e479bcb5c33bfcae9189f6853209ab","status":"active","text":"Pregnancies exposed only to valproate had a higher major congenital malformation rate than pregnancies exposed only to carbamazepine, and valproate-containing polytherapy regimens carried higher risk than regimens without valproate.","confidence":0.99,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_59e479bcb5c33bfcae9189f6853209ab"}],"concepts":[{"public_id":"co_1bf81d74bfb721669343ffaa2ba78fcd","status":"active","name":"lamotrigine","description":"An antiepileptic drug evaluated for its relationship to malformation risk and dose response.","types":["drug"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_1bf81d74bfb721669343ffaa2ba78fcd"},{"public_id":"co_310024f31a4f17cdc1600b1b0579fffc","status":"active","name":"UK Epilepsy and Pregnancy Register","description":"A prospective register that collected pregnancy outcome data for women with epilepsy.","types":["registry"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_310024f31a4f17cdc1600b1b0579fffc"},{"public_id":"co_578a8a7d7ec28eada2be8f35dcfe527a","status":"active","name":"valproate","description":"An antiepileptic drug evaluated for its association with malformation risk.","types":["drug"],"aliases":["valproic acid"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_578a8a7d7ec28eada2be8f35dcfe527a"},{"public_id":"co_62eb0f9230dd3168c9d2b165d2bf5bf1","status":"active","name":"dose-response relationship","description":"A pattern in which malformation risk changes with increasing dose of a drug.","types":["relationship"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_62eb0f9230dd3168c9d2b165d2bf5bf1"},{"public_id":"co_797c50c408140996d2b5dfb3833c0148","status":"active","name":"carbamazepine","description":"An antiepileptic drug evaluated for its association with malformation risk.","types":["drug"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_797c50c408140996d2b5dfb3833c0148"},{"public_id":"co_a224769b046c379b909a8bede6e6e113","status":"active","name":"antiepileptic drug exposure","description":"In utero exposure to antiepileptic medications during pregnancy.","types":["exposure"],"aliases":["AED exposure","AEDs"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_a224769b046c379b909a8bede6e6e113"},{"public_id":"co_b41da2012af71c5e3f7c6d824de0be69","status":"active","name":"women with epilepsy","description":"Pregnant women diagnosed with epilepsy and included in the pregnancy register.","types":["population"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_b41da2012af71c5e3f7c6d824de0be69"},{"public_id":"co_bfaca34ff810990185adf63631a94947","status":"active","name":"monotherapy","description":"Use of a single antiepileptic drug during pregnancy.","types":["treatment regimen"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_bfaca34ff810990185adf63631a94947"},{"public_id":"co_dbb7fcac0603b6ed76e1d6ef9b940008","status":"active","name":"polytherapy","description":"Use of more than one antiepileptic drug during pregnancy.","types":["treatment regimen"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_dbb7fcac0603b6ed76e1d6ef9b940008"},{"public_id":"co_dc47d7bc8b2b2a7cf364997911d538c3","status":"active","name":"major congenital malformation","description":"A serious structural abnormality present at birth and recorded as the primary outcome in early infancy.","types":["outcome"],"aliases":["MCMs","MCM"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_dc47d7bc8b2b2a7cf364997911d538c3"}],"external_ids":{"DOI":"10.1136/jnnp.2005.074203","ArXiv":null,"PubMed":16157661,"PubMedCentral":"PMC2077578","MAG":2119186079,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://jnnp.bmj.com/content/jnnp/77/2/193.full.pdf","landing_url":"https://www.semanticscholar.org/paper/3337e258321c2555637f7529a0e7dd78eb1adb92","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":null,"status":"BRONZE","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":631668,"paper_uid":"549bae2b-562d-43b8-be42-310140399383","canonical_identity":{"paper_id":631668,"paper_uid":"549bae2b-562d-43b8-be42-310140399383","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/13512160"}